Literature DB >> 27255828

Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.

Belén Callejón-Leblic1, Tamara García-Barrera2, Jesús Grávalos-Guzmán3, Antonio Pereira-Vega3, José Luis Gómez-Ariza4.   

Abstract

UNLABELLED: Lung cancer is one of the ten most common causes of death worldwide, so that the search for early diagnosis biomarkers is a very challenging task. Bronchoalveolar lavage fluid (BALF) provides information on cellular and biochemical epithelial surface of the lower respiratory tract constituents and no previous metabolomic studies have been performed with BALF samples from patients with lung cancer. Therefore, this fluid has been explored looking for new contributions in lung cancer metabolism. In this way, two complementary metabolomics techniques based on direct infusion high resolution mass spectrometry (DI-ESI-QTOF-MS) and gas chromatography mass spectrometry (GC-MS) have been applied to compare statistically differences between lung cancer (LC) and control (C) BALF samples, using partial least square discriminant analysis (PLS-DA) in order to find and identify potential biomarkers of the disease. A total of 42 altered metabolites were found in BALF from LC. The metabolic pathway analysis showed that glutamate and glutamine metabolism pathway was mainly altered by this disease. In addition, we assessed the biomarker specificity and sensitivity according to the area under the receiver operator characteristic (ROC) curves, indicating that glycerol and phosphoric acid were potential sensitive and specific biomarkers for lung cancer diagnosis and prognosis. BIOLOGICAL SIGNIFICANCE: The search for early diagnosis of lung cancer is a very challenging task because of the high mortality associated to this disease and its critical linkage to the initiation of treatment. Bronchoalveolar lavage fluid provides information on cellular and biochemical epithelial surface of the lower respiratory tract constituents and no previous metabolomic studies have been performed with BALF samples from patients with lung cancer. Since BALF is in close interaction with lung tissue it is a more representative sample of lung status than other peripheral biofluids as blood or urine studied in previous works. Therefore, this study represents an innovative contribution in this topic that complement previous investigations about lung cancer, opening up new possibilities for understanding the pathogenesis of this disease and the use of efficient biomarkers. Therefore, this fluid has been explored looking for new contributions in lung cancer metabolism. In this way, two complementary metabolomic techniques based on direct infusion high resolution mass spectrometry (DI-ESI-QTOF-MS) and gas chromatography mass spectrometry (GC-MS) have been applied to compare statistically significant differences between lung cancer (LC) and control (C) BALF samples, using partial least square discriminant analysis (PLS-DA) in order to find and identify potential biomarkers of the disease. A total of 42 altered metabolites were found in BALF from LC. The metabolic pathway analysis showed that glutamate and glutamine metabolism pathway was mainly altered by this disease. In addition, we assessed the biomarker specificity and sensitivity according to the area under the receiver operator characteristic (ROC) curves, indicating that glycerol and phosphoric acid were potential sensitive and specific biomarkers for lung cancer diagnosis and prognosis.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Bronchoalveolar fluid; Direct infusion mass spectrometry; Gas chromatography mass spectrometry; Lung cancer; Metabolomics

Mesh:

Substances:

Year:  2016        PMID: 27255828     DOI: 10.1016/j.jprot.2016.05.030

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  11 in total

1.  Metabolic signatures of four major histological types of lung cancer cells.

Authors:  Swee Ling Lim; Zhunan Jia; Yonghai Lu; Hui Zhang; Cheng Teng Ng; Boon Huat Bay; Han Ming Shen; Choon Nam Ong
Journal:  Metabolomics       Date:  2018-08-31       Impact factor: 4.290

Review 2.  Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review.

Authors:  Li Yu; Kefeng Li; Xiaoye Zhang
Journal:  Oncotarget       Date:  2017-11-11

3.  Untargeted metabolomics profiles delineate metabolic alterations in mouse plasma during lung carcinoma development using UPLC-QTOF/MS in MSE mode.

Authors:  Huan Wu; Yang Chen; Zegeng Li; Xianhua Liu
Journal:  R Soc Open Sci       Date:  2018-09-19       Impact factor: 2.963

4.  Neutral Desorption Extractive Electrospray Ionization Mass Spectrometry Analysis Sputum for Non-Invasive Lung Adenocarcinoma Detection.

Authors:  Qiaoling Zheng; Jianyong Zhang; Xinchen Wang; Wenxiong Zhang; Yipo Xiao; Sheng Hu; Jianjun Xu
Journal:  Onco Targets Ther       Date:  2021-01-15       Impact factor: 4.147

5.  [Advances on Collection and Analysis of Volatile Organic Compounds 
in the Diagnosis of Lung Cancer].

Authors:  Ling Guo; Hong Wu; Qiang Li; Chuan Xu; Yuyang Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-11-20

6.  Serum Metabolic Disturbances in Lung Cancer Investigated through an Elaborative NMR-Based Serum Metabolomics Approach.

Authors:  Anjana Singh; Ved Prakash; Nikhil Gupta; Ashish Kumar; Ravi Kant; Dinesh Kumar
Journal:  ACS Omega       Date:  2022-01-31

Review 7.  Therapeutic Potential of Glutamine Pathway in Lung Cancer.

Authors:  Enyu Tang; Siyang Liu; Zhiming Zhang; Rixin Zhang; Dejing Huang; Tong Gao; Tianze Zhang; Guangquan Xu
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

8.  A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection.

Authors:  Lun Zhang; Jiamin Zheng; Rashid Ahmed; Guoyu Huang; Jennifer Reid; Rupasri Mandal; Andrew Maksymuik; Daniel S Sitar; Paramjit S Tappia; Bram Ramjiawan; Philippe Joubert; Alessandro Russo; Christian D Rolfo; David S Wishart
Journal:  Cancers (Basel)       Date:  2020-03-07       Impact factor: 6.639

9.  Urinary Volatomic Expression Pattern: Paving the Way for Identification of Potential Candidate Biosignatures for Lung Cancer.

Authors:  Khushman Taunk; Priscilla Porto-Figueira; Jorge A M Pereira; Ravindra Taware; Nattane Luíza da Costa; Rommel Barbosa; Srikanth Rapole; José S Câmara
Journal:  Metabolites       Date:  2022-01-04

10.  Monoacylglycerol lipase deficiency in the tumor microenvironment slows tumor growth in non-small cell lung cancer.

Authors:  Melanie Kienzl; Carina Hasenoehrl; Kathrin Maitz; Arailym Sarsembayeva; Ulrike Taschler; Paulina Valadez-Cosmes; Oliver Kindler; Dusica Ristic; Sofia Raftopoulou; Ana Santiso; Thomas Bärnthaler; Luka Brcic; Lisa Hahnefeld; Robert Gurke; Dominique Thomas; Gerd Geisslinger; Julia Kargl; Rudolf Schicho
Journal:  Oncoimmunology       Date:  2021-09-11       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.